目的 分析辽宁省肿瘤医院2020-2022年小分子酪氨酸激酶抑制剂的使用情况以及变化趋势，为临床安全合理经济用药提供参考依据。方法 收集2020-2022年辽宁省肿瘤医院小分子酪氨酸激酶抑制剂使用数据，分析销售金额、用药频度（DDDs）、限定日费用（DDC）以及排序比（B/A）。结果 2020-2022年小分子酪氨酸激酶抑制剂销售金额逐年增长。奥希替尼连续3年销售金额稳居第1位。仑伐替尼销售金额大幅增长，而吉非替尼销售金额大幅下降。奥希替尼、埃克替尼、吉非替尼的DDDs近3年稳居前3位。仑伐替尼DDDs大幅上升，而索拉非尼DDDs大幅下降。普拉替尼、赛沃替尼和洛拉替尼的DDC值偏高。埃克替尼、吉非替尼、厄洛替尼、索拉非尼和达可替尼DDC值较低。从B/A可以看出，2022年埃克替尼和吉非替尼的B/A>1，赛沃替尼、培唑帕尼和阿来替尼的排序比<1。结论 2020-2022年辽宁省肿瘤医院小分子酪氨酸激酶抑制剂的使用总体上较为合理，但仍需进一步加强监管力度，保障患者用药的安全、有效和经济。

Objective To analyze the usage and variation tendency of small-molecule tyrosine kinase inhibitors in Liaoning Cancer Hospital & Institute from 2020 to 2022, and provide references for standardizing the management and rational application. Methods Consumption sum, DDDs, DDC, and drug B/A of small-molecule tyrosine kinase inhibitors in Liaoning Cancer Hospital& Institute from 2020 to 2022 were analyzed statistically. Results From 2020 to 2022, the sales amount of small-molecule tyrosine kinase inhibitors increased year by year. Osimertinib ranked first in sales in three years. Lenvatinib sales increased significantly, while gefitinib sales decreased significantly. Osimertinib, icotinib, and gefitinib have been in the top three for DDDs in the past three years. Lenvatinib DDDs rose sharply, while sorafenib DDDs decreased sharply. Pralsetinib, savolitinib, and lorlatinib have high DDC values. Icotinib, gefitinib, erlotinib, sorafenib, and dacomitinib DDC values are low. It can be seen from the ranking ratio that the B/A of icotinib and gefitinib in 2022 is >1, and the B/A of savolitinib, pazopanib, and alectinib is <1. Conclusion From 2020 to 2022, the use of small-molecule tyrosine kinase inhibitors in Liaoning Cancer Hospital & Institute is generally reasonable. However, it is still necessary to further strengthen supervision to ensure the safety, effectiveness and economy of treatment drugs.

R979.1

辽宁省肿瘤医院质谱课题项目（ZP202019）